ReviewNutrients2011
Probiotics in inflammatory bowel diseases and associated conditions.
Review in Nutrients, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Guideline
- Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study.BioMed research international · 2014Trial
- Prebiotic Treatment During Pregnancy Prevents Social Deficits Associated with Autism Spectrum Disorder-like Behavior Induced by Maternal Immune Activation.Microorganisms · 2025Article
- Efficacy and safety probiotics as adjuvant treatment for Crohn's disease: a meta-analysis of randomized controlled trials.Current research in food science · 2025Article
- Mitigating digestive disorders: Action mechanisms of Mediterranean herbal active compounds.Open life sciences · 2024Review
- Probiotics for inflammatory bowel disease: Is there sufficient evidence?Open life sciences · 2024Review
- Leaky Gut and the Ingredients That Help Treat It: A Review.Molecules (Basel, Switzerland) · 2023Review
- Article
- Microbial Modulation in Inflammatory Bowel Diseases.Immune network · 2022Review
- Considerations for determining safety of probiotics: A USP perspective.Regulatory toxicology and pharmacology : RTP · 2022Review
- Bioactive fish collagen peptides weaken intestinal inflammation by orienting colonic macrophages phenotype through mannose receptor activation.European journal of nutrition · 2022Article
- Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.Journal of advanced research · 2022Review
- Lactic Acid Bacteria Isolated from Fresh Vegetable Products: Potential Probiotic and Postbiotic Characteristics Including Immunomodulatory Effects.Microorganisms · 2022Article
- Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases.Journal of clinical medicine · 2021Review
- Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases.Nutrients · 2020Review
- Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways.World journal of gastroenterology · 2020Review
- Probiotics in Medicine: A Long Debate.Frontiers in immunology · 2020Review
- Inhibitory Effects of theFrontiers in immunology · 2020Article
- Increased Functional Foods' Consumption and Mediterranean Diet Adherence May Have a Protective Effect in the Appearance of Gastrointestinal Diseases: A Case⁻Control Study.Medicines (Basel, Switzerland) · 2019Article
- Probiotics, prebiotics and amelioration of diseases.Journal of biomedical science · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A complex set of interactions between the human genes encoding innate protective functions and immune defenses and the environment of the intestinal mucosa with its microbiota is currently considered key to the pathogenesis of the chronic inflammatory bowel diseases (IBD). Probiotics offer a method to potentially alter the intestinal microbiome exogenously or may provide an option to deliver microbial metabolic products to alter the chronicity of intestinal mucosal inflammation characterizing IBD. At present, there is little evidence for the benefit of currently used probiotic microbes in Crohn's disease or associated conditions affecting extra-intestinal organs. However, clinical practice guidelines are now including a probiotic as an option for recurrent and relapsing antibiotic sensitive pouchitis and the use of probiotics in mild ulcerative colitis is provocative and suggests potential for benefit in select patients but concerns remain about proof from trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.